Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex
<p><strong>Background:</strong></p> <p>Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.</p> <p>&l...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Heart Association
2022
|
| _version_ | 1826308609940652032 |
|---|---|
| author | Patone, M Mei, XW Handunnetthi, L Dixon, S Zaccardi, F Shankar-Hari, M Watkinson, P Khunti, K Harnden, A Coupland, CAC Channon, KM Mills, NL Sheikh, A Hippisley-Cox, J |
| author_facet | Patone, M Mei, XW Handunnetthi, L Dixon, S Zaccardi, F Shankar-Hari, M Watkinson, P Khunti, K Harnden, A Coupland, CAC Channon, KM Mills, NL Sheikh, A Hippisley-Cox, J |
| author_sort | Patone, M |
| collection | OXFORD |
| description | <p><strong>Background:</strong></p>
<p>Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.</p>
<p><strong>Methods:</strong></p>
<p>A self-controlled case series study of people ages 13 years or older vaccinated for COVID-19 in England between December 1, 2020, and December 15, 2021, evaluated the association between vaccination and myocarditis, stratified by age and sex. The incidence rate ratio and excess number of hospital admissions or deaths from myocarditis per million people were estimated for the 1 to 28 days after sequential doses of adenovirus (ChAdOx1) or mRNA-based (BNT162b2, mRNA-1273) vaccines, or after a positive SARS-CoV-2 test.</p>
<p><strong>Results:</strong></p>
<p>In 42 842 345 people receiving at least 1 dose of vaccine, 21 242 629 received 3 doses, and 5 934 153 had SARS-CoV-2 infection before or after vaccination. Myocarditis occurred in 2861 (0.007%) people, with 617 events 1 to 28 days after vaccination. Risk of myocarditis was increased in the 1 to 28 days after a first dose of ChAdOx1 (incidence rate ratio, 1.33 [95% CI, 1.09–1.62]) and a first, second, and booster dose of BNT162b2 (1.52 [95% CI, 1.24–1.85]; 1.57 [95% CI, 1.28–1.92], and 1.72 [95% CI, 1.33–2.22], respectively) but was lower than the risks after a positive SARS-CoV-2 test before or after vaccination (11.14 [95% CI, 8.64–14.36] and 5.97 [95% CI, 4.54–7.87], respectively). The risk of myocarditis was higher 1 to 28 days after a second dose of mRNA-1273 (11.76 [95% CI, 7.25–19.08]) and persisted after a booster dose (2.64 [95% CI, 1.25–5.58]). Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91–99] versus 16 [95% CI, 12–18]). In women younger than 40 years, the number of excess events per million was similar after a second dose of mRNA-1273 and a positive test (7 [95% CI, 1–9] versus 8 [95% CI, 6–8]).</p>
<p><strong>Conclusions:</strong></p>
<p>Overall, the risk of myocarditis is greater after SARS-CoV-2 infection than after COVID-19 vaccination and remains modest after sequential doses including a booster dose of BNT162b2 mRNA vaccine. However, the risk of myocarditis after vaccination is higher in younger men, particularly after a second dose of the mRNA-1273 vaccine.</p> |
| first_indexed | 2024-03-07T07:22:11Z |
| format | Journal article |
| id | oxford-uuid:d3576d3a-aead-42ec-a36b-ed2664026ae2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:22:11Z |
| publishDate | 2022 |
| publisher | American Heart Association |
| record_format | dspace |
| spelling | oxford-uuid:d3576d3a-aead-42ec-a36b-ed2664026ae22022-10-24T13:27:47ZRisk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sexJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d3576d3a-aead-42ec-a36b-ed2664026ae2EnglishSymplectic ElementsAmerican Heart Association2022Patone, MMei, XWHandunnetthi, LDixon, SZaccardi, FShankar-Hari, MWatkinson, PKhunti, KHarnden, ACoupland, CACChannon, KMMills, NLSheikh, AHippisley-Cox, J<p><strong>Background:</strong></p> <p>Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.</p> <p><strong>Methods:</strong></p> <p>A self-controlled case series study of people ages 13 years or older vaccinated for COVID-19 in England between December 1, 2020, and December 15, 2021, evaluated the association between vaccination and myocarditis, stratified by age and sex. The incidence rate ratio and excess number of hospital admissions or deaths from myocarditis per million people were estimated for the 1 to 28 days after sequential doses of adenovirus (ChAdOx1) or mRNA-based (BNT162b2, mRNA-1273) vaccines, or after a positive SARS-CoV-2 test.</p> <p><strong>Results:</strong></p> <p>In 42 842 345 people receiving at least 1 dose of vaccine, 21 242 629 received 3 doses, and 5 934 153 had SARS-CoV-2 infection before or after vaccination. Myocarditis occurred in 2861 (0.007%) people, with 617 events 1 to 28 days after vaccination. Risk of myocarditis was increased in the 1 to 28 days after a first dose of ChAdOx1 (incidence rate ratio, 1.33 [95% CI, 1.09–1.62]) and a first, second, and booster dose of BNT162b2 (1.52 [95% CI, 1.24–1.85]; 1.57 [95% CI, 1.28–1.92], and 1.72 [95% CI, 1.33–2.22], respectively) but was lower than the risks after a positive SARS-CoV-2 test before or after vaccination (11.14 [95% CI, 8.64–14.36] and 5.97 [95% CI, 4.54–7.87], respectively). The risk of myocarditis was higher 1 to 28 days after a second dose of mRNA-1273 (11.76 [95% CI, 7.25–19.08]) and persisted after a booster dose (2.64 [95% CI, 1.25–5.58]). Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91–99] versus 16 [95% CI, 12–18]). In women younger than 40 years, the number of excess events per million was similar after a second dose of mRNA-1273 and a positive test (7 [95% CI, 1–9] versus 8 [95% CI, 6–8]).</p> <p><strong>Conclusions:</strong></p> <p>Overall, the risk of myocarditis is greater after SARS-CoV-2 infection than after COVID-19 vaccination and remains modest after sequential doses including a booster dose of BNT162b2 mRNA vaccine. However, the risk of myocarditis after vaccination is higher in younger men, particularly after a second dose of the mRNA-1273 vaccine.</p> |
| spellingShingle | Patone, M Mei, XW Handunnetthi, L Dixon, S Zaccardi, F Shankar-Hari, M Watkinson, P Khunti, K Harnden, A Coupland, CAC Channon, KM Mills, NL Sheikh, A Hippisley-Cox, J Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex |
| title | Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex |
| title_full | Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex |
| title_fullStr | Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex |
| title_full_unstemmed | Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex |
| title_short | Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex |
| title_sort | risk of myocarditis after sequential doses of covid 19 vaccine and sars cov 2 infection by age and sex |
| work_keys_str_mv | AT patonem riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT meixw riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT handunnetthil riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT dixons riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT zaccardif riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT shankarharim riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT watkinsonp riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT khuntik riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT harndena riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT couplandcac riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT channonkm riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT millsnl riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT sheikha riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex AT hippisleycoxj riskofmyocarditisaftersequentialdosesofcovid19vaccineandsarscov2infectionbyageandsex |